Transforming cancer therapeutics
Aucentra Therapeutics is an Australian clinical stage oncology biopharma company with integrated R&D and clinical capabilities
Established in 2017, Aucentra Therapeutics develops breakthrough drugs to address unmet medical needs for some of the most severe cancers. Our novel compounds will transform cancer treatment by providing targeted and efficacious medicines with less side effects. Aucentra’s deep pipeline of proprietary anti-cancer drugs include candidates for the treatment of leukaemia, glioblastoma, colorectal, pancreas, ovary, breast and lung. Our expertise in drug development, manufacture and clinical trials facilitates an expediated process from discovery all the way through to the patient.
A PIPELINE OF ORAL DRUG CANDIDATES
Our pipeline consists of first-in-class or best-in-class novel kinase inhibitors in pre-clinical and clinical stage development.
In particular, we focus on targeting cyclin dependent kinases (CDKs), known for their over-expression in cancer cells. We develop highly selective small molecule inhibitors that are more efficacious and have less side effects than standard treatments and, in many instances, are able to treat cancers with no current therapeutic options.
UNIQUE DISCOVERY CAPABILITIES
We are experts in small molecule drug discovery and development. Our capabilities span medicinal and pharmaceutical chemistry, cell-based and enzymatic assays, in vivo pharmacokinetics, in vivo efficacy in disease models, and clinical and biomarker development.
PARTNERING FOR SUCCESS
We complement our in-house expertise with global partnerships to accelerate products to the clinic. Partnering and investment are key to our success.
CONTACT
If you’d like to learn more about Aucentra, please send us an email.
© 2024 AUCENTRA (ABN 48 623 009 861)
All rights reserved.
Lab image photography by Chris Oaten.